Skip to main content
PRME
NASDAQ Life Sciences

Prime Medicine Posts Q3 Loss, Pro-Forma Cash of $209.5M and Runway Through 2027

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$3.9
Mkt Cap
$705.556M
52W Low
$2.67
52W High
$5.91
52W Position info
46% above low
Off High info
34% below high
Rel. Volume info
1.6× avg
Market data snapshot near publication time

PRME sits 46% above its 52-week low of $2.67.

Summary

Prime Medicine reported a $39.0 million Q3 net loss and disclosed pro-forma cash of about $209.5 million including $134.7 million of net offering proceeds, funding operations through 2027.


Key Events · Earnings and Guidance · PRME

  • Q3 Net Loss of $39.0 Million

    Net loss was $39.0 million, or $0.22 per share, versus $50.6 million a year earlier; loss from operations was $39.9 million.

  • Pro-Forma Cash of $209.5 Million

    Pro-forma cash, equivalents, investments and restricted cash of approximately $209.5 million after the November offering, with runway through 2027.

  • Offering Nets $134.7 Million

    The underwritten offering closed with the full greenshoe, raising $143.7 million gross and about $134.7 million net of discounts and expenses.

  • Spending Falls Year Over Year

    R&D was $34.1 million versus $44.0 million and G&A $10.0 million versus $11.2 million in the prior-year quarter.


Analysis · PRME · Life Sciences

The Q3 release itself is close to what Reuters already reported — a $39.0 million net loss and $39.9 million operating loss — but the 8-K adds the number that matters most for a company that carried a going-concern warning in its last 10-Q: pro-forma cash of roughly $209.5 million after the $134.7 million net offering proceeds, enough to fund operations through 2027. That removes near-term financing risk and covers the planned PM359 BLA in the first half of 2027 plus initial PM577a and PM647 data in 2027. Spending is also falling, with R&D down to $34.1 million from $44.0 million a year earlier.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, PRME was trading at $3.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $705.6M. The 52-week trading range was $2.67 to $5.91. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

PRME - Latest Insights

PRME
Nov 12, 2026, 4:11 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $3.89
Real-time Price: $4.22 info
Change: +$0.3249 (+8%) info
Market Cap: $764.503M info
PRME
Nov 12, 2026, 4:02 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $3.89
Real-time Price: $4.22 info
Change: +$0.325 (+8%) info
Market Cap: $764.503M info
PRME
Nov 10, 2026, 9:41 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $3.76
Real-time Price: $4.22 info
Change: +$0.4555 (+12%) info
Market Cap: $764.503M info
PRME
Nov 10, 2026, 4:43 PM EST
Filing Type: 424B5
Importance Score:
8
Price at Filing: $3.79
Real-time Price: $4.22 info
Change: +$0.425 (+11%) info
Market Cap: $764.503M info
PRME
Nov 10, 2026, 4:06 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.80
Real-time Price: $4.22 info
Change: +$0.415 (+11%) info
Market Cap: $764.503M info